These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34530385)

  • 1. Novel theranostic agent for PET imaging and targeted radiopharmaceutical therapy of tumour-infiltrating immune cells in glioma.
    Foster A; Nigam S; Tatum DS; Raphael I; Xu J; Kumar R; Plakseychuk E; Latoche JD; Vincze S; Li B; Giri R; McCarl LH; Edinger R; Ak M; Peddagangireddy V; Foley LM; Hitchens TK; Colen RR; Pollack IF; Panigrahy A; Magda D; Anderson CJ; Edwards WB; Kohanbash G
    EBioMedicine; 2021 Sep; 71():103571. PubMed ID: 34530385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical ImmunoPET Imaging of Glioblastoma-Infiltrating Myeloid Cells Using Zirconium-89 Labeled Anti-CD11b Antibody.
    Nigam S; McCarl L; Kumar R; Edinger RS; Kurland BF; Anderson CJ; Panigrahy A; Kohanbash G; Edwards WB
    Mol Imaging Biol; 2020 Jun; 22(3):685-694. PubMed ID: 31529407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the immunologically "cold" tumor microenvironment after treatment with immune checkpoint inhibitors utilizing PET imaging of CD4 + and CD8 + T cells in breast cancer mouse models.
    Lu Y; Houson HA; Gallegos CA; Mascioni A; Jia F; Aivazian A; Song PN; Lynch SE; Napier TS; Mansur A; Larimer BM; Lapi SE; Hanker AB; Sorace AG
    Breast Cancer Res; 2024 Jun; 26(1):104. PubMed ID: 38918836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a
    Ren J; Xu M; Chen J; Ding J; Wang P; Huo L; Li F; Liu Z
    Theranostics; 2021; 11(1):304-315. PubMed ID: 33391476
    [No Abstract]   [Full Text] [Related]  

  • 5. Target engagement of an anti-MT1-MMP antibody for triple-negative breast cancer PET imaging and beta therapy.
    Magro N; Oteo M; Romero E; Ibáñez-Moragues M; Lujan VM; Martínez L; Vela O; López-Melero ME; Arroyo AG; Garaulet G; Martínez-Torrecuadrada JL; Mulero F; Morcillo MA
    Nucl Med Biol; 2024; 136-137():108930. PubMed ID: 38833768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced Theranostic Efficacy of
    Chen Z; Yang Q; Song L; Qiu Y; Wang T; Wu S; Huang W; Sun X; Wang A; Kang L
    Mol Pharm; 2024 May; 21(5):2544-2554. PubMed ID: 38588328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD38-Targeted Theranostics of Lymphoma with
    Kang L; Li C; Rosenkrans ZT; Huo N; Chen Z; Ehlerding EB; Huo Y; Ferreira CA; Barnhart TE; Engle JW; Wang R; Jiang D; Xu X; Cai W
    Adv Sci (Weinh); 2021 May; 8(10):2001879. PubMed ID: 34026426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade.
    Zhao L; Pang Y; Zhou Y; Chen J; Fu H; Guo W; Xu W; Xue X; Su G; Sun L; Wu H; Zhang J; Wang Z; Lin Q; Chen X; Chen H
    Signal Transduct Target Ther; 2024 Jun; 9(1):142. PubMed ID: 38825657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Infiltrating Myeloid Cells in Gastric Cancer Using a Pretargeted Imaging Strategy Based on Bio-Orthogonal Diels-Alder Click Chemistry and Comparison with
    Zhang Y; Lin Q; Wang T; Shi D; Fu Z; Si Z; Xu Z; Cheng Y; Shi H; Cheng D
    Mol Pharm; 2022 Jan; 19(1):246-257. PubMed ID: 34816721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model.
    Natarajan A; Mayer AT; Reeves RE; Nagamine CM; Gambhir SS
    Mol Imaging Biol; 2017 Dec; 19(6):903-914. PubMed ID: 28247187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and preclinical evaluation of a novel bifunctional macrocyclic chelator for theranostics of cancers.
    Xu J; Cai F; Luo Z; Fan W; Dai J; Cui J; Li S; Geng C; Zheng Q; Wang Z; Tang X
    Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2618-2633. PubMed ID: 35347438
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Privé BM; Derks YHW; Rosar F; Franssen GM; Peters SMB; Khreish F; Bartholomä M; Maus S; Gotthardt M; Laverman P; Konijnenberg MW; Ezziddin S; Nagarajah J; Heskamp S
    Eur J Nucl Med Mol Imaging; 2022 May; 49(6):2064-2076. PubMed ID: 34932154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ITGB2 as a prognostic indicator and a predictive marker for immunotherapy in gliomas.
    Xu H; Zhang A; Han X; Li Y; Zhang Z; Song L; Wang W; Lou M
    Cancer Immunol Immunother; 2022 Mar; 71(3):645-660. PubMed ID: 34313821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas.
    Kim JE; Patel MA; Mangraviti A; Kim ES; Theodros D; Velarde E; Liu A; Sankey EW; Tam A; Xu H; Mathios D; Jackson CM; Harris-Bookman S; Garzon-Muvdi T; Sheu M; Martin AM; Tyler BM; Tran PT; Ye X; Olivi A; Taube JM; Burger PC; Drake CG; Brem H; Pardoll DM; Lim M
    Clin Cancer Res; 2017 Jan; 23(1):124-136. PubMed ID: 27358487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Checkpoint Inhibitors in Human Glioma Microenvironment.
    Ghouzlani A; Kandoussi S; Tall M; Reddy KP; Rafii S; Badou A
    Front Immunol; 2021; 12():679425. PubMed ID: 34305910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction and Application of a PD-L1-Targeted Multimodal Diagnostic and Dual-Functional Theranostics Nanoprobe.
    He C; Guo Y; Zhou N; Wang Z; Liu T; Xu X; Wang F; Zhu H; Yang Z; Yang X; Xia L
    Int J Nanomedicine; 2024; 19():5479-5492. PubMed ID: 38863646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DFO-Km: A Modular Chelator as a New Chemical Tool for the Construction of Zirconium-89-Based Radiopharmaceuticals.
    Salih AK; Dominguez Garcia M; Raheem SJ; Ahiahonu WK; Price EW
    Inorg Chem; 2023 Dec; 62(50):20806-20819. PubMed ID: 37751491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody.
    Christensen C; Kristensen LK; Alfsen MZ; Nielsen CH; Kjaer A
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1302-1313. PubMed ID: 31883023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
    Perk LR; Visser GW; Vosjan MJ; Stigter-van Walsum M; Tijink BM; Leemans CR; van Dongen GA
    J Nucl Med; 2005 Nov; 46(11):1898-906. PubMed ID: 16269605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remodeling of the tumor microenvironment via disrupting Blimp1
    Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
    Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.